Abstract | AIM: to report the prevalence, risk factors, management and long-term outcome of thyroid disorders caused by INFalpha in patients with chronic hepatitis C. PATIENTS AND METHODS: RESULTS: 58 patients developed thyroid disorder (8.9%). Mean age was 50.6+/-13 years; sex ratio: 1 M/2 F; the anti-TPO antibodies were positive before onset antiviral treatment in 9 patients (13.8%). 26 patients developed hypothyroidism (44.8%), 9 patients developed hyperthyroidism (15.5%) and among them 3 cases of Grave's disease. Biphasic thyroiditis occurred in 21 patients (36.2%), anti-TPO increase during treatment in 2 patients (3.5%) without hypothyroidism. The dysthyroidism was more frequent in risk in female gender (p<0.05) and in the group with positive antiTPO antibodies before treatment (p<0.02). CONCLUSION: Female gender and positive antiTPO antibodies are the predictive factors of development of the thyroid dysfunction during INFalpha therapy.
|
Authors | N Kabbaj, M M Guedira, H El Atmani, M El Alaoui, M Mohammadi, K Benabed, H Lachkar, A Benaïssa |
Journal | Annales d'endocrinologie
(Ann Endocrinol (Paris))
Vol. 67
Issue 4
Pg. 343-7
(Sep 2006)
ISSN: 0003-4266 [Print] France |
PMID | 17072240
(Publication Type: Journal Article)
|
Chemical References |
- Antiviral Agents
- Autoantibodies
- Interferon-alpha
- Thyrotropin
|
Topics |
- Antiviral Agents
(adverse effects, therapeutic use)
- Autoantibodies
(blood)
- Cohort Studies
- Female
- Genotype
- Hepacivirus
(genetics)
- Hepatitis C, Chronic
(drug therapy)
- Humans
- Interferon-alpha
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Retrospective Studies
- Thyroid Diseases
(chemically induced)
- Thyroid Gland
(immunology)
- Thyrotropin
(blood)
- Viral Load
|